Literature DB >> 24377625

Korean prostate cancer patients have worse disease characteristics than their American counterparts.

Dong Il Kang1, Jae Il Chung, Hong Koo Ha, Kweonsik Min, Jangho Yoon, Wansuk Kim, Won Ik Seo, Pil moon Kang, Soo Jin Jung, Isaac Yi Kim.   

Abstract

BACKGROUND: Although the PSA test has been used in Korea for over 20 years, the incidence of prostate cancer has risen, and the associated mortality has increased about 13-fold over the 20-year period. Also, several investigators have suggested that Asians in America are more likely to present with more advanced prostate cancer than Caucasians. We compared the characteristics of native Koreans and Americans (Caucasians and African- Americans) undergoing radical prostatectomies in Korea and the US.
MATERIALS AND METHODS: Study subjects comprised patients at Korean and US hospitals from 2004 to 2012 who had undergone radical prostatectomies. We compared the characteristics of the subjects, including age, preoperative prostate-specific antigen (PSA) levels, body mass index (BMI), Gleason score, and pathological T stage.
RESULTS: In total, 1,159 males (502 Koreans, 657 Americans) were included. The Korean and American patients had mean ages of 67.1 ± 6.6 and 59.2 ± 6.7 years, respectively. The mean preoperative PSAs were 15.4 ± 17.9 and 6.2 ± 4.6 ng/mL (p=0.0001) and the mean BMIs were 23.6 ± 2.6 and 28.7 ± 4.4 kg/m2 (p=0.0001), respectively. Pathological localized prostate cancer represented 71.7% of cases for Koreans and 77.6% for Americans (p=0.07). According to age, Koreans had higher T stages than Americans in their 50s (p=0.021) and higher Gleason scores than Americans in all age groups. According to PSA, Koreans had higher Gleason scores than Americans for PSA >10 ng/mL (p<0.05). According to prostate size and Gleason scores, Koreans had higher PSA values than Americans (p<0.01).
CONCLUSIONS: These results show that Korean patients have elevated risk of malignant prostate cancers, as indicated by the significantly higher Gleason scores and PSAs, suggesting a need for novel prostate cancer treatment strategies in Korea.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24377625     DOI: 10.7314/apjcp.2013.14.11.6913

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy.

Authors:  T-H Kim; Y-S Ha; S H Choi; E S Yoo; B W Kim; S-J Yun; W-J Kim; Y S Kwon; T G Kwon
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

2.  Combination of multiparametric magnetic resonance imaging and transrectal ultrasound-guided prostate biopsies is not enough for identifying patients eligible for hemiablative focal therapy for prostate cancer.

Authors:  Young Hyo Choi; Ji Woong Yu; Min Yong Kang; Hyun Hwan Sung; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Hwang Gyun Jeon
Journal:  World J Urol       Date:  2019-01-02       Impact factor: 4.226

3.  The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  Int Urol Nephrol       Date:  2017-09-13       Impact factor: 2.370

4.  A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.

Authors:  Ping Qi; Ming Chen; Li-xiu Zhang; Rui-xia Song; Zhen-hua He; Zhi-ping Wang
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

5.  Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.

Authors:  Hye Won Lee; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2015-02-16       Impact factor: 2.153

6.  Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.

Authors:  Hongzoo Park; Sang Wook Lee; Geehyun Song; Tae Wook Kang; Jae Hung Jung; Hyun Chul Chung; Sung Jin Kim; Chang Hoo Park; Jong Yeon Park; Tae Young Shin; In Bum Suh; Jeong Hyun Kim
Journal:  J Korean Med Sci       Date:  2018-03-12       Impact factor: 2.153

Review 7.  Updates on Cancer Epidemiology in Korea, 2018.

Authors:  Sun-Seog Kweon
Journal:  Chonnam Med J       Date:  2018-05-25

8.  Incidence of Prostate Cancer according to Metabolic Health Status: a Nationwide Cohort Study.

Authors:  Jong Wook Kim; Sun Tae Ahn; Mi Mi Oh; Du Geon Moon; Kyungdo Han; Hong Seok Park
Journal:  J Korean Med Sci       Date:  2019-01-31       Impact factor: 2.153

9.  Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.

Authors:  Won Ik Seo; Pil Moon Kang; Dong Il Kang; Jang Ho Yoon; Wansuk Kim; Jae Il Chung
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

10.  Changes in Clinical Characteristics of Patients with an Initial Diagnosis of Prostate Cancer in Korea: 10-Year Trends Reported by a Tertiary Center.

Authors:  Ji Eun Heo; Hyun Kyu Ahn; Jinu Kim; Byung Ha Chung; Kwang Suk Lee
Journal:  J Korean Med Sci       Date:  2018-02-05       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.